Jane Street Group LLC Sells 24,392 Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM)

Jane Street Group LLC lowered its stake in Actinium Pharmaceuticals, Inc. (NYSE:ATNM) by 37.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 40,837 shares of the company’s stock after selling 24,392 shares during the period. Jane Street Group LLC owned approximately 0.13% of Actinium Pharmaceuticals worth $77,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of ATNM. Renaissance Technologies LLC bought a new stake in Actinium Pharmaceuticals during the second quarter worth $142,000. Bank of New York Mellon Corp boosted its stake in Actinium Pharmaceuticals by 28.3% in the second quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after buying an additional 19,035 shares in the last quarter. Wellington Management Group LLP bought a new position in Actinium Pharmaceuticals in the third quarter valued at about $112,000. The Manufacturers Life Insurance Company acquired a new position in Actinium Pharmaceuticals during the second quarter worth about $92,000. Finally, Creative Financial Designs Inc. ADV raised its stake in Actinium Pharmaceuticals by 183.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 63,785 shares of the company’s stock worth $120,000 after acquiring an additional 41,250 shares in the last quarter. Institutional investors and hedge funds own 27.50% of the company’s stock.

Actinium Pharmaceuticals Price Performance

Shares of ATNM opened at $1.22 on Thursday. The business’s 50-day moving average is $1.37. The company has a market capitalization of $38.06 million, a P/E ratio of -0.88 and a beta of 0.12. Actinium Pharmaceuticals, Inc. has a 1 year low of $1.10 and a 1 year high of $10.24.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. StockNews.com cut shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. Stephens reiterated an “overweight” rating and issued a $5.00 price objective on shares of Actinium Pharmaceuticals in a report on Tuesday, November 19th. Finally, HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Actinium Pharmaceuticals in a research report on Friday, November 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.40.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).